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Dr Chandan Sen  
Editor in Chief 
Antioxidants & redox signaling 
Turin, August 9, 2019 
 
RE: Submission of revision for manuscript ARS-2019-7799.R1 entitled “Subcellular 
characterization of NAD+ biosynthesis in metastatic melanoma by using organelle-specific 
biosensors” by Gaudino and colleagues for publication in your journal as Original Research 
Communication. 
 
Dear Dr Sen, 
Along with all the authors, I would like to submit the re-revised version for the above-referenced 
paper. In your email of August 8 to me, you wrote that “additional experimental data are needed”; 
however, I did not find any indication concerning novel experimental data, which were considered 
acceptable by all 5 reviewers. In fact, following our first review, we received comments from 5 
reviewers, 4 of whom have no further issues at this point and are ok with the revised manuscript. 
The fifth reviewer suggests further stylistic modifications, most of which are trivial, but does not ask 
for any additional experimental work. I do not want to sound argumentative, but if you carefully 
read the modifications required by reviewer 5, you will see that most of them are really within 
individual writing freedom. However, this reviewer in his/her general comment writes that “the 
science could be sound”. I find this sentence really unfair: whether the science is sound or not is for 
the reviewer to decide based upon solid motivations. If the reviewer does not find solid criticism to 
the science, then he/she should not use derogatory s ntences such as the one above. 
Today, I have carefully gone through all of his/her suggestions and re-wrote the relevant sentences 
accordingly.  
All modifications are highlighted in red in the revised text. 
Together with all the authors I now hope this work may be rapidly acceptable for publication in 





Silvia Deaglio, MD, PhD 
Associate Professor of Medical Genetics 
University of Turin 
Turin, Italy 
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REVIEWER 1 
The revised Figure 1 has demonstrated organelle-specific localization for the sensor. 
Author’s reply:  
Dear Reviewer 1, 
Thanks for acknowledging the organelle specificity of the sensor. 
 
REVIEWER 2 
The original manuscript has now been improved enough, following reviewers' suggestions. 
Author’s reply:  
Dear Reviewer 2, 
Thanks for the positive evaluation of our work. 
 
REVIEWER 3 
The revised manuscript submitted by the authors have satisfactorily addressed the concerns of this 
reviewer and could be accepted for publication. 
Author’s reply:  
Dear Reviewer 3, 






This is a revised manuscript. Although the authors have made some effort to address most of my 
previous comments, there are still serious concerns relating to the readability and comprehension 
of the manuscript. Too many complex sentences, especially the new additions. In this case, it is 
challenging to appreciate the merit of the science, which could be sound, but gets murky in 
convoluted details of awkward sentences.   
Author’s reply:  
Dear Reviewer 5, 
Thanks for a novel and very thorough stylistic re-review of our paper. As you will see, I have accepted 
most of your suggestions. However, I am sorry to read that the “science could be sound”. I believe 
that it is your job as a reviewer to judge the soundness of “the science”. If you think it is not sound, 
then you have to say what part of the science is not sound and why. I am also sorry to read that our 
sentences are “convoluted” and “murky”. Again, this should be appropriately detailed. From the 
examples you make, modifications required are truly minimal, and sometimes arguable. In any case, 
as you will see from the detailed reply to your issues, I have accepted most of them and explained 
the reasons why I rejected some. I now hope you will be satisfied, as were the other four reviewers. 
 
Reviewer’s comment: INTRODUCTION: “First of all, NAD is essential…” Delete “First of all”. 
Author’s reply: modified as requested. 
 
Reviewer’s comment: INTRODUCTION “Open issues concern the biology of the system…” What 
does this mean? 
Author’s reply 
Sentence has been rephrased.  
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Reviewer’s comment: INTRODUCTION “Several efforts were made to elucidate…” Revise to read, 
“Several efforts have been made to elucidate… 
Author’s reply 
As these efforts were well into the past and finished (we refer to published papers!) I am quite sure 
the past tense is correct. However, to avoid any additional discussion, I modified it as requested. 
 
Reviewer’s comment: INTRODUCTION “maintenance of cellular NAD+ pool is pursued through the 
re-oxidation of…” Change “pursue” to “achieve”. 
Author’s reply 
Modified as requested. 
 
Reviewer’s comment: INTRODUCTION In details…” Revise to read “Briefly…” The scanty information 
presented is not considered “In details”.  
Author’s reply 
Modified as requested. 
 
Reviewer’s comment: INTRODUCTION Last paragraph, line 88 “To the aim, we exploited…” Revise 
to read, “In addition, we exploited…” 
Author’s reply 
Here we really mean to say “To the aim”. It does not add to anything else.  
 
Reviewer’s comment: RESULTS “Subcellular NAD+ concentrations effects…” 
Lines 38-40 “Therefore, we hypothesized an NMN-driven rescue of NAD+ levels upon NAMPT 
chemical inhibition.” What does this mean? Please revise. 
Author’s reply. Sentence was modified as requested 
 
Reviewer’s comment: RESULTS FK866 predominantly in nuclei…and in mitochondria…” The 
statistical significance in comparing the nuclei content seems to be a suspect. Please address. 
Author’s reply 
This specific experiment was performed 5 independent times. The relevant comparison here is 
between cells that were treated with FK866 alone and cells that were supplemented with NR before 
treating with FK866 (as described in Methods). 
The specific numbers we obtained from the “ratio of ratio” (again details are in Methods) are: 







Data were statistically analyzed using a paired t test. The results is p=0.0004 and is considered by 
GraphPad software highly significant. 
 
Reviewer’s comment: RESULTS  Lines 48-50 “In the latter, NR preserved NAD+ levels…FK856 
exposure.” What does this sentence mean? Consider simplifying it. Similar concern in clarity is 
applicable to the sentence, lines 52-60 “Treatment of A375 with QA…increased NAD levels only in 
mitochondria. Furthermore, selectively in these organelles…FK866-induced NAD depletion…” 
Please revise the two sentences cited here. 
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Author’s reply 
Sentences were modified to improve readability. 
 
Reviewer’s comment: RESULTS   Proof-of-principle of the… 
Line 45 “The result is in keeping with literature suggesting…” Revise to read, “The result is consistent 
with the literature, suggesting…” Line 50-52 “…with our data indicating that NAMPT is mostly 
cytosolic enzyme…” This phrase seems as redundant and therefore, not necessary. 
Author’s reply 
Modified as indicated 
 
Reviewer’s comment: DISCUSSION   Lines 33-37 “Even if promising, initial trials have limited clinical 
responses, also because they were burdened by significant…. Please revise for clarity of meaning. 
Author’s reply 
Thanks for pointing this out, sentence was rephrased. 
 
Reviewer’s comment: DISCUSSION   Paragraph starting with “Characterization of subcellular NAD 
pool…”, line 59 “…support increased cellular growth rates they reprogram NDA+ biosynthesis. 





Reviewer’s comment: DISCUSSION   Lines 28-30 “Indeed, for these cells, HPLC measurements 
already detected more than the double of NAD+ content…” Revise to read, “Indeed, for these cells, 





Reviewer’s comment: DISCUSSION   Lines 15-23 “The current view of the field is that NRKs are 
preferentially located in cytosol…no evidence is available indicating NRK activity in this organelle.” 
Revise to read, “The current view of the field is that NRKs are preferentially located in the 





Reviewer’s comment: DISCUSSION   Lines 47-52 “Our data, both biochemical and biosensor 
based…arguing in favor of direct NAD biosynthesis in these organelles.” Revise to read “Our data, 
both biochemical and biosensor based…arguing in favor of direct NAD biosynthesis in the 
organelle.”  
Author’s reply 
I did not modify this, but kept the original version. Mitochondria is plural, the organelle is singular, 
so I prefer these organelles.  
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Reviewer’s comment: DISCUSSION   Lines 54-6, starting with Chowdhry et al….” to “NRK knockdown 
or dual inhibition…” on the next page (all in red) should be revised for the sake of clarity; the 




Reviewer’s comment: DISCUSSION   Lines 18-20 “…however, we cannot exclude the cytosolic 
import of NAD, a possible enzyme translocation mechanism or cell type dependence of NAD+…” 





Reviewer’s comment: DISCUSSION   Lines 25-33 “At the concentrations used…regulated transport 
of these metabolites.” This is a long and tortuous sentence. Please fragment it to two easy to 





Reviewer’s comment: DISCUSSION   Line 40 “…compartment the NR >>NAD+ pathway is NAMPT-
dependent rather than NRK-dependent.” What does this phrase men? Please clarify.  
Author’s reply 
This refers to data cointained in references 5 and 36. It has been rephrased to improve clarity. 
 
Reviewer’s comment: DISCUSSION   Line 49 “Overall, our data provide proof-of-principle…to 
monitor NAD+ fluctuations occurring in…” Revise to read, “Overall, our data provide proof-of-
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Abstract 
Aim: NAD+ plays central roles in a wide array of normal and pathological conditions. Inhibition of 
NAD+ biosynthesis can be exploited therapeutically in cancer, including melanoma. To obtain 
quantitation of NAD+ levels in live cells and to address the issue of the compartmentalization of 
NAD+ biosynthesis, we exploited a recently described, genetically-encoded NAD+ biosensor (LigA-
cpVENUS), which was targeted to the cytosol, mitochondria and nuclei of BRAF-V600E A375 
melanoma cells, a model of metastatic melanoma (MM).
Results: FK866, a specific inhibitor of nicotinamide phosphoribosyltransferase (NAMPT), the main 
NAD+-producing enzyme in MM cells, was used to monitor NAD+ depletion kinetics at the subcellular 
level in biosensor-transduced A375 cells. In addition, we treated FK866-blocked A375 cells with 
NAD+ precursors, including nicotinamide, nicotinic acid, nicotinamide riboside and quinolinic acid, 
highlighting an organelle-specific capacity of each substrate to rescue from NAMPT block. 
Expression of NAD+ biosynthetic enzymes was then biochemically studied in isolated organelles, 
revealing presence of NAMPT in all three cellular compartments, while NAPRT was predominantly 
cytosolic and mitochondrial, and NRK mitochondrial and nuclear. In keeping with biosensor data, 
QPRT was expressed at extremely low levels. 
Innovation & Conclusions: Throughout this work, we validated the use of genetically encoded NAD+ 
biosensors to characterize subcellular distribution of NAD+ production routes in MM. The chance of 
real time monitoring of NAD+ fluctuations after chemical perturbations, together with a deeper 
comprehension of the cofactor biosynthesis compartmentalization, strengthens the foundation for 
a targeted strategy of NAD+ pool manipulation in cancer and metabolic diseases.
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Introduction
Nicotinamide adenine dinucleotide (NAD+) is a vital, ubiquitous and multifunctional cofactor 
regulating a wide range of biological processes (10,29). NAD+ is essential as electron acceptor donor 
in glycolytic, tricarboxylic acid cycle (TCA) and oxidative phosphorylation redox reactions. The 
equilibrium existing between its oxidized (NAD+) or reduced forms (NADH) mediates cellular 
antioxidation mechanisms, as well as cell redox state homeostasis, energy metabolism and 
mitochondrial functions (62). In addition, NAD+ is the substrate of enzymes with fundamental roles 
in gene expression and cell signaling, independent of its redox properties. This large family of 
NAD+ consuming enzymes includes adenosine diphosphate (ADP)-ribose transferases (ARTs) and 
poly ADP-ribose polymerases (PARPs), sirtuins (SIRTs) and cyclic ADP-ribose hydrolases 
(CD38/CD157) (27,57). Through their functional activities of post-translational modifications 
(ADP-ribosylation and deacetylation reactions), or by calcium signaling mobilization, these 
enzymes regulate gene transcription, cell differentiation, cell cycle progression, DNA repair, 
chromatin stability, among other biological processes (12), representing connecting elements 
between the metabolic state of a cell and its signaling and transcriptional activities. 
The subcellular localization of specific biosynthetic pathways remains to be fully elucidated. Several 
efforts have been made to elucidate where NAD+ biosynthesis occurs and whether there are 
exchanges between compartments (17,18,30,31,40,46). The maintenance of cellular NAD+ pool 
is achieved through the re-oxidation from NADH or through the active synthesis of the pyridine 
nucleotide. Briefly, NAD+ is synthesized through one de novo bio-synthetic pathway, starting from 
tryptophan/quinolinic acid (QA) and controlled by the enzyme quinolinate 
phosphoribosyltransferase (QPRT) (6,29) and three salvage pathways involving nicotinamide 
(NAM), nicotinic acid (NA), and nicotinamide riboside (NR) (12,34). Each pathway is controlled by 
a rate-limiting enzyme, specifically nicotinamide phosphoribosyl transferase (NAMPT), nicotinate 
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phosphoribosyltransferase (NAPRT) and nicotinamide riboside kinase (NRK). Among these 
pathways, the reaction controlled by NAMPT is the most relevant in mammalian cells (48), as the 
NAMPT substrate, NAM, is released by the main NAD+ consuming enzymes, such as sirtuins and 
PARPs, connecting NAD+ synthesis and degradation in a functional loop. NAMPT is frequently 
over-expressed in hematological and solid tumors (22,35,52). Our recent data showed that 
transformation of melanocytes to metastatic melanoma (MM) is accompanied by a net increase 
in global NAD+ levels, particularly in the BRAF-mutated subset (2). Further elevation of NAD+ 
levels occurs in cells that acquire resistance to BRAF inhibitors, an event accompanied by 
metabolic reprogramming and NAMPT overexpression (2,3). An increase in NAD+ may be needed 
to sustain cell proliferation and growth of MM cells and it may directly affect NAD+ consumption 
pathways in an organelle-specific manner.
Following this hypothesis, we studied NAD+ bioavailability by dissecting the subcellular location 
of its biosynthesis. To the aim, we exploited a genetically-encoded fluorescent biosensor 
(9,15,19) to directly monitor free NAD+ concentrations in subcellular compartments of MM cells 
and we connected this information to the biochemical evaluation of subcellular distribution of 
NAD+ biosynthetic enzymes (NBEs). 
Results 
Generation of A375 cells stably expressing organelle-specific NAD+ biosensor
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To study the compartmentalization of NAD+ biosynthesis, we used the BRAFV600E-mutated A375 
cell line as a melanoma model. Both, BRAF inhibitor sensitive (S) and resistant (BiR) A375 were 
transduced with lentiviruses carrying the DNA coding for organelle-specific biosensor proteins (9). 
The biosensor contains an organelle specific sequence (as detailed in M&M), and the NAD+-binding 
site of a bacterial DNA ligase (LigA1b-LigA1a). A cpVENUS fluorescent protein is connected to the 
bipartite NAD+ binding domain of the enzyme. The structure allows biosensor fluorescence to be 
turned off when NAD+ is bound. Based on their cpVENUS-fluorescence, transduced cells were flow-
sorted to obtain stably expressing cells. Confocal microscopy shows the specificity of the biosensor 
in reaching the target compartment (Figure 1 A-B-C), as determined by co-localization of the 
biosensor signal (green) with the actin cytoskeleton (red), TOM20 (magenta) or DAPI (blue). 
Organelle-specific effects of NAMPT inhibition
To study NAD+-depletion kinetics induced by inhibiting the major mammalian NAD+ biosynthetic 
pathway, we treated biosensor-encoding A375 cells with the well-known NAMPT inhibitor FK866 
(2,38). The biosensor works by decreasing its fluorescence at 488 nm in the presence of increased 
levels of NAD+, while its 405 nm fluorescence is unaffected by substrate variations and can be used 
to normalize the biosensor expression levels. Therefore, a decrease in NAD+ levels leads to an 
increase of the 488 nm/405 nm fluorescence ratio (9,15,19). From previous works, it is known that 
FK866 treatment leads to a significant drop of total intracellular NAD+ levels beginning few hours 
after treatment (26). Consistently, a time-lapse confocal microscopy analysis of A375 cells treated 
with FK866 (25nM), confirmed a net drop in cytosolic, mitochondrial and nuclear NAD+ levels 
steadily increasing over the 4 hours observation time (Figure 2A, movies 1-2-3). In order to obtain 
quantitative measurements, we then measured NAD+ concentrations by cytofluorimetric analysis, 
at the fixed time point of 16 hours after FK866 treatment, when >90% of intracellular NAD+ is 
depleted, according to previous data (9). In these conditions, we observed a sharp increase in the 
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488 nm/405 nm fluorescence ratio in FK886-treated cells in all the sub-cellular compartments 
(Figure 2B). The mean fluorescence ratio was augmented by 3010% (p=0.0002), 3814% 
(p<0.0001) and 329% (p<0.0001) in the cytosol, mitochondria and nuclei, respectively. Figure 2C is 
a representative example of the biosensor behavior under FK866 treatment. The dot plot on the left 
depicts changes in fluorescence at 488 nm in relation to 405 nm of cell expressing the biosensor or 
the cpVENUS only. No modification in the 488 nm fluorescence of the cpVENUS could be highlighted 
after treatment with FK866, confirming specificity of the results (relative histograms on the right). 
Subcellular NAD+ concentrations and effects of NMN on subcellular NAD+ levels 
In order to quantify NAD+ fluctuations, we generated specific calibration curves for the cytosolic, 
the nuclear and the mitochondrial biosensors (Figure 3) (9,15,19). To do so, cells expressing 
cytosolic and nuclear biosensors were saponin-permeabilized to allow exogenous NAD+ (used in a 
range of concentrations between 0 and 4 mM for cytosol and from 0 to 3mM for nucleus) to enter 
the cell or nucleus, as previously described (9). For the mitochondrial biosensor, saponin 
permeabilization was followed by rapid treatment with the ion channel-forming peptide alamethicin 
(AlaM), which renders mitochondria permeable to low-molecular-mass molecules (4,23,37). In this 
conditions, exogenous NAD+ (from 0 to 10mM) entered in the organelle, inducing a linear reduction 
of the sensor fluorescence according to increasing NAD+ concentrations. Table 1 shows fluorescence 
ratio 488 nm/405 nm calculations obtained from each biosensor and normalized on relative 
cpVENUS 488 nm/405 nm variations (for cytosolic and nuclear biosensors the mean of 4 replicates 
is shown, while 3 replicates are shown for mitochondrial biosensor). These cytofluorimetric 
measurements of fluorescence variations at each NAD+ concentration were used to build specific 
sigmoidal curves. Lastly, by interpolating fluorescence ratio of non-permeabilized cells expressing 
the cytosolic biosensor to the relative titration curve, we found basal cytosolic mean values of NAD+ 
in A375 cells of 26174M. The same experimental approach was used for the cells expressing the 
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nuclear biosensor, detecting in this compartment a basal nuclear concentration of 25985M, while 
NAD+ concentrations in the mitochondria were in the range of 499154M. Treatment with FK866 
diminished cytosolic, nuclear and mitochondrial NAD+ concentrations to values <0.7μM, below 
which the system is no longer sensitive. The amount of this NAD+ depletion is in line with previously 
reported HPLC measurements of whole lysates from FK866-treated A375 cells (2). 
Next, to further validate the system in our model, we studied the effects of nicotinamide 
mononucleotide (NMN), the product of the reaction catalyzed by NAMPT, on NAD+ levels with or 
without treatment with FK866. After being produced by NAMPT, NMN is converted into NAD+ by 
nicotinamide mononucleotide adenylyl-transferases (NMNATs), which are known to be expressed 
in the nucleus (NMNAT1), in the cytosol and Golgi (NMNAT-2) and in the mitochondria (NMNAT-
3)(7,45,46). Therefore, we hypothesized that supplementation of NMN to cells could rescue NAD+ 
levels in the presence of NAMPT inhibitors. As expected, treatment of A375 cells with NMN 
increased basal NAD+ levels, in all cellular compartments and particularly in the cytosol (Figure 3C). 
After treating cells with the NMNAT substrate, we detected a consistent reduction of fluorescence 
ratio of 142% (p=0.001) in the cytosol corresponding to an increase in NAD+ to 1621606M. In 
the nuclei, a reduction of fluorescence in the range of 84% (p=0.0037) corresponded to 
651280M NAD+. A moderate but consistent fluorescence reduction of 93% (p=0.043) was also 
detected in mitochondria, where we measured an increase of the cofactor to a mean value of 
20121855M. Importantly, the combination of NMN and FK866, reverted the FK866-induced 
fluorescence ratio from 365% to 67% (p=0.01) in the cytosol, from 3513% to 86% (p=0.002) in 
the mitochondria and from 287% to 168% (p=0.021) in the nuclei. The NMN-dependent rescue 
of NAMPT block is statistically significant when considering fluorescence ratios, and NAD+ levels 
recover from <0.7M to 167M in cytosol, to 125M in mitochondria and to 9M into the nucleus. 
Topography of NAD+ Biosynthesis: NAM and NA primarily affect cytosolic NAD+ levels
Page 12 of 56
Please destroy all records after use for peer review. Mary Ann Liebert Inc., 140 Huguenot Street, New Rochelle, NY 10801





























































CONFIDENTIAL. For Peer Review Only
Gaudino F., et al.
8
To obtain a complete topography of NAD+ biosynthesis in MM, we then studied the efficacy of 
different NAD+ precursors including NAM, NA, NR and QA, in sustaining NAD+ biosynthesis and in 
rescuing from FK866-mediated NAD+ depletion in the various compartments. We first treated cells 
with NAM and NA, substrates of the most relevant NAD+ producing pathways in MM cells. NAM is 
recycled to NAD+ in a two-step salvage pathway in which NAMPT, using the ribose-5-phosphate 
group of phosphoribosylpyrophosphate (PRPP) catalyzes a phosphoribosyl transferase reaction 
converting NAM to NMN (31). Treatment of cells with NAM led to a significant increase in cytosolic 
NAD+ basal levels, as expected based on the documented cytosolic expression of NAMPT (2,17,40) 
(Figure 4A). In fact, in this compartment, the fluorescence ratio was reduced by 177% (p=0.004), 
corresponding to an increase in basal NAD+ levels to 1930980M. A slighter decrease in the 
fluorescence ratio was observed in the nuclei, where we measured an increase in basal levels of the 
cofactor to 489±195M, whereas no changes were measured in mitochondria. An additional 
mechanism leading to NAD+ accumulation could be linked to block of NAD+ intracellular 
consumption, as NAM is a powerful noncompetitive inhibitor of NAD+-consuming enzymes (SIRTs 
and PARPs) (8,31,51). Consistently, even when added to A375 cells treated with FK866, NAM was 
able to partially prevent NAD+ loss. In fact, in the cytosol, we observed a rescue from FK866-induced 
NAD+ depletion, with fluorescence ratios going from 2914% to 1513% (p=0.02, NAD+ 
concentration of 36M), in mitochondria from 4620% to 1420% (p=0.005), while in the nuclear 
compartment from 376% to 238% (p=0.003). The observed NAM-driven rescue of NAD+ levels, 
would essentially reflect the inhibition of sirtuin activities in the three compartments, while in the 
nuclei PARPs activity block could also contribute to the outcome.
NA is the substrate of NAPRT, which converts NA into nicotinic acid mononucleotide (NAMN) via the 
Press-Handler pathway (11,29). NA was effective in the cytosol, as well in nuclei and mitochondria, 
both in increasing compartmentalized NAD+ basal levels and in countering the effects of NAMPT 
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inhibition (Figure 4B). The highest NA-dependent increase in basal NAD+ was detected in the cytosol 
(134% of fluorescence ratio reduction, p=0.013, NAD+ concentration of 976550M), followed by 
mitochondria (1031550M). The evidence of a NA/NAPRT-mediated rescue from FK866-induced 
NAD+ depletion, confirms the reported finding that NAPRT-mediated NAD+ production limits the 
action of NAMPT inhibitors used in cancer treatment (42,53).
Topography of NAD+ Biosynthesis: NR and QA showed an organelle-specific impact on NAD+ levels
We then tested the effects of NR and QA on subcellular NAD+ levels. NR is an additional salvageable 
NAD+ precursor via the NRKs-mediated pathway. NR conversion to NAD+ is initiated by 
phosphorylation of NR to NMN by NR kinases (NRKs) (47,56). Studying the subcellular capacity of 
NR in sustaining NAD+ production in MM, we found NR to be effective in increasing basal NAD+ levels 
in cytosol (760557M) and in nuclei (533166M) (Figure 5A). However, NR was able to counter 
the effects of FK866 predominantly in nuclei (from 275% to 195% p=0.0004) and in mitochondria 
(from 3712% to 1411% p=0.007) (Figure 5A). In mitochondria of cells supplemented with NR and 
treated with FK866, NAD+ levels were kept between 50-240M, thus preventing its drop after FK866 
exposure. Lastly, treatment of A375 with QA, an intermediate precursor of the 8 steps-de novo 
synthesis pathway, increased NAD+ levels only in mitochondria. Furthermore, QA offered partial and 
weak protection from FK866-induced NAD+ depletion selectively in mitochrondria (Figure 5B). This 
finding is in line with the reported low expression of QPRT in MM (2,29).Together, these results 
support the idea of a dominant NAD+ production via the recycling pathways in MM cells, with a clear 
preference for the cytosolic NAM-NAMPT. In the cytosol NAPRT can be considered a second active 
NAD+ producer, while in the organelles, NRK appears to play a key role as NAD+ biosynthetic enzyme.
Subcellular localization of NAD+ biosynthetic enzymes
Subcellular distribution of NBEs remains an incompletely understood aspect of NAD+ physiology, 
with increasing evidence suggesting that NAD+ biosynthesis is compartmentalized in a cellular- and 
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tissue-dependent way (17,46). To determine the subcellular expression pattern of NBEs in A375 cells 
in exponential growth phase and to interpret data obtained with the organelle-specific biosensors, 
we used confocal microscopy and biochemical analyses. Western blot analyses were performed on 
cytosol and isolated mitochondria and nuclei. Confocal microscopy was used to support biochemical 
analysis. By comparing expression levels of the four NBEs, we confirmed that NAMPT is the 
dominant NBEs (Figure 6A-C, left panel). We then dissected NBEs subcellular localization by looking 
at protein distribution in the separate compartments. A percentage of expression for the different 
compartments was determined by dividing pixel intensity of the specific bands pertaining to a given 
compartment by the sum of the pixel intensities of the bands pertaining to all compartments. 
Western blot analysis showed that NAMPT is mostly cytosolic (84.16% of localization, Figure 6A), 
with low mitochondrial (10.74%) and nuclear (5.1%) expression. Organelles purity was confirmed by 
using specific markers (anti-Vinculin, -tubulin,-actin antibodies specifically highlight cytosolic 
fraction; anti-hadha and –cytochrome C antibodies identify mitochondrial enrichment while anti-
H2A antibody was used for nuclear compartment detection). NAPRT was essentially cytosolic 
(92.2%), with minor fractions present in mitochondria (5.7%) and nuclei (2.1%). Conversely, NRK 
was mostly mitochondrial (67.2%) and nuclear (32.7%). QPRT was detectable at very low levels only 
in cytosol and in mitochondria (not shown). Organelle purity was confirmed by using specific 
markers. NBEs subcellular distribution was confirmed by confocal microscopy, by using organelle-
specific markers and a software co-localization tool (Figure 6C, right panel). The panel on the left 
shows the overlay of the NBE under analysis and the compartment specific marker. The three panels 
on the right show expression of the NBE under analysis in the indicated compartment.
Proof-of-principle of the use of the biosensor to monitor NAD+ levels
Lastly, we decided to use the biosensor to compare NAD+ levels in A375 cells before (S) and after 
the acquisition of resistance to BRAF inhibitors (BiR). These cellular models offered us a strategic 
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and clinically relevant example of cancer metabolic adaptation suitable for characterization of NAD+ 
biosynthesis. In keeping with our prior data showing that A375/BiR cells are characterized by higher 
expression of NAMPT and constitutive higher levels of NAD+ (2), the biosensors showed a more 
pronounced sensitivity to NAD+-depletion through NAMPT inhibition. Specifically, as evidenced by 
a higher fluorescence variations, upon FK866 treatment, A375/BiR cells were more severely NAD+-
depleted than /S variants, at least in the cytosol and nucleus (Figure 7). These results, not only 
confirm that NAMPT is the master regulator of NAD+ biosynthesis in A375/BiR cells, but also 
evidence a compartmentalized response to NAMPT inhibition in the two cell lines. Specifically, a 
highly significant difference in response to FK866 was highlighted in the cytosol and the nuclei, while 
no significant difference was observed in mitochondria. This result is consistent with the literature 
suggesting a differential behavior of mitochondria compared to the cytosol or the nuclei in the 
dynamics of metabolites exchange (40,53). In addition, we found that, in A375, the most 
mitochondrial expressed NBE is NRK, potentially explaining the lower sensitivity of A375/BiR 
mitochondria to NAMPT inhibition. 
Overall, these data validate NAD+ biosensors as tools to understand whether the main pathways 
responsible for NAD+ production differ across subcellular compartments or under chemical 
perturbations. 
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Discussion
Because of its essential role and ubiquitous presence, alterations of NAD+ concentrations are 
associated with a large number of pathological conditions, including metabolic diseases like obesity, 
diabetes and insulin resistance, inflammation and immune responses (16,46,64). A decrease in NAD+ 
levels is also a hallmark of aging and aging-associated pathologies, such as neurodegeneration and 
motor function decline. For these reasons, NAD+ boosting molecules or inhibitors of the NADases 
received remarkable attention as antiaging agents or co-adjuvants for maintaining NAD+ 
homeostasis (46). On the other hand, a significant branch of research on NAD+ metabolism 
documented increased levels of the cofactor during tumorigenesis (2,52), thus rendering NAD+ 
metabolism an attractive therapeutic target in cancer treatment. Inhibitors against NAMPT, the 
major intracellular NBE, are under development for phase I and II clinical trials for patients with 
ovarian, pancreatic and rectal cancers or with hematological malignancies, including multiple 
myeloma and chronic lymphocytic leukemia (28,58,60). Even if some clinical responses were 
observed, patients treated with NAMPT inhibitors experienced significant toxicity, including 
thrombocytopenia and gastrointestinal complications. The modest success of FK866 in cancer 
patients, may be explained by the activation of rescue pathways that can overcome NAMPT block 
and restore NAD+ levels through alternative routes. Most important in this context is NAPRT, the 
rate-limiting enzyme in the metabolism of dietary NA into NAD+. Epigenetic regulation of NAPRT 
leads to gene silencing in some tumors, while in the cases in which it is over-expressed, the enzyme 
is responsible for the failure of NAMPTi-based treatments (11,42). Like NA, NR can be introduced 
through diet, but it is also the by-product of extracellular NMN dephosphorylation reaction carried 
out by CD73 (53), an ectoenzyme involved in the generation of adenosine, in turn a powerful 
immunosuppressant. Recent reports indicate that NR, via NRK activity, maintains cancer NAD+ 
homeostasis in the presence of NAMPTi, contributing to treatment failure (14,25,53). In addition, 
Page 17 of 56
Please destroy all records after use for peer review. Mary Ann Liebert Inc., 140 Huguenot Street, New Rochelle, NY 10801





























































CONFIDENTIAL. For Peer Review Only
Gaudino F., et al.
13
the dynamic NAD+/NADH balance impacts on the redox state of cancer cells. In fact, tumors possess 
higher levels of reactive oxygen species (ROS), rendering them more sensitive to changes in the 
redox status (13,33). In this context, NAD(H)/NADP(H) balance regulates glutathione reductase (GR) 
and thioredoxin reductase (TR) activities, major components of the antioxidant defense system 
(24,39,59). Specifically, reducing equivalents from NADPH are used to regenerate reduced 
glutathione (GSH) from the oxidized form (GSSG), fueling the ROS scavenging system of the cell (59). 
For this reason, the availability of NAD+ precursors and their subcellular-specific employment could 
regulate the activity of GSH/GSSG system in an organelle-dependent way. The prevalence of a 
cytosolic GSH pool likely makes it sensitive to the presence of an active NAM/NAMPT axis and to its 
pharmacological inhibition. In addition, G6PD, which is the major source of NADPH, can also be 
activated post-transcriptionally by SIRT2 dependent deacetylation (59). 
Characterization of subcellular NAD+ pools and compartmentalized NAD+ biosynthetic pathways are 
pivotal in order to tailor therapeutic interventions, modulating the balance between NAD+ 
consumption and production. This work was undertaken with the dual aim of obtaining a clearer 
picture of NAD+ biosynthesis in BRAF-mutated melanoma cells and to set-up conditions to follow its 
modifications in live cells. To address our aims, out of all the tools developed in the last 10 years for 
real time measuring of NAD+ or NAD+/NADH levels (50,65), we used a recently devised genetically-
encoded NAD+ biosensor (9), which was targeted to the cytosol, nuclei and mitochondria. The choice 
of this biosensor is based on its intrinsic properties I) as a ratiometric tool specific for NAD+ 
detection, II) optimal binding affinity for physiological cellular NAD+ concentrations. In addition, III) 
the biosensor is easy to manipulate and has equally easy readouts.
BRAF-V600E A375 cells were used as experimental model, as it was shown that, in order to support 
increased cellular growth rates, they reprogrammed NAD+ biosynthesis by overexpressing NAMPT. 
This NAMPT overexpression is even stronger during BRAF inhibitors resistance development (2,3), a 
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frequent clinical complication incurring in metastatic melanoma of patients. The basal NAD+ 
concentration in the cytosol and nuclei of A375 cells in the exponential growth phase was estimated 
at 260μM and at 499μM in mitochondria (Figure 8), in keeping with previously reported values for 
total intracellular free NAD+ levels ranging between 200 and 500μM (10,29,31,57,61). In addition, 
in basal conditions, the recently estimated NAD+ pool concentrations in cultured mammals and 
murine derived cell lines (HEK293T, HeLa, U2OS, NIH3T3) move from 60μM to 120μM for nuclei and 
cytosol (9,29,50), increasing to ~300μM in mitochondria (9,10,29). These reported 
compartmentalized NAD+ concentrations are tightly dependent on the cell type. For this reason, it 
was not surprising for us to find the aforementioned concentration of free NAD+ in cytosol, nuclei 
and mitochondria of A375 cells. Indeed, for these cells, HPLC measurements already detected more 
than double the NAD+ content compared to normal melanocytes (2). Moreover, by combining 
dynamic measurements using live cells and organelle fractionation, we can conclude that NAMPT is 
quantitatively the most expressed NAD biosynthetic enzyme in A375 cells and undoubtedly the 
dominant one in the cytosol (Figure 8). If we look at the nuclear compartment, the prevalent NBE is 
NRK followed by NAMPT. Cytosol and nuclei are considered exchangeable compartments for the 
diffusion of NAD+ pools (31). This concept, together with the revealed high expression levels of NRK 
in nuclei, could explain similar levels of NAD+ concentrations between cytosol and nucleus of A375. 
By combining two well established protocols for mitochondria purification (21,32,63), we found that 
mitochondria of MM cells appear to be equipped predominantly with NRK and possibly with lower 
levels of NAMPT and NAPRT (Figure 8). Even though mitochondrial NAD+ contents can reach up to 
70% of total intracellular NAD+ (1), how its levels are maintained remains a matter of debate. Two 
processes, glycolysis and NAD+ biosynthesis, directly link cytoplasmic and mitochondrial NAD+ pools 
(54). The NADH produced by glycolysis is transported into the mitochondrial matrix by NAD/NADH 
redox shuttles (62), providing reducing equivalents for the TCA cycle and electron transport chain 
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(ETC). The former process reduces O2 to water and NADH to NAD+ in order to produce ATP, 
generating mitochondrial NAD+ levels much higher than the other cellular compartment (43). In 
addition, maintenance of NAD+ levels in the compartment is also dependent on salvaging NAM 
produced by NAD+-consuming enzymes. The current view of the field is that NRKs are preferentially 
located in the cytosol and nucleoplasm, and while it is accepted that NR is the preferred NAD+ 
precursor for mitochondrial NAD+ synthesis (29,40,53), no evidence is available indicating NRK 
activity in mitocondria. One of the current hypotheses about mitochondrial NAD+ is that, it can be 
maintained by the NMNAT3 conversion of NMN or by the membrane transport of NAD+ precursors 
(NAM, NMN) or even NAD+ itself. Indeed, while some demonstrated that NAD+ is unable to cross 
the mitochondrial membrane and that pyridine nucleotides are instead broken down to the 
corresponding nucleosides (40,44,53,54), others affirmed that only intact NAD+ can restore 
depleted mitochondria NAD+ levels (17,20). Even if the first eukaryotic mitochondrial NAD+ carrier, 
named Ndt1p, was identified in Saccharomyces cerevisiae (55) and in 2009 Palmieri et al. identified 
a chloroplast and mitochondrial NAD+ carrier protein in Arabidopsis thaliana (41), no mammalian 
transporter for NAD+ has yet been found. For these reasons, whether there is a complete NAD+ 
biosynthetic apparatus or a system transport for NAD+ in mitochondria remains unclear (17). Our 
data, both biochemical and biosensor based, suggest that NRK is present in the mitochondria, at 
least in A375 melanoma cells, arguing in favor of direct NAD+ biosynthesis in these organelles. In 
addition, the prevalent NRK expression in mitochondria, could suggest the use of NRK inhibitors. 
Consistently, recent data by Chowdhry et al. indicated that NRK-dependent synthesis of NAD+ 
causes the failure of NAMPTis and that both NRK knockdown or dual inhibition of NAMPT and NRK 
lowered the dose of FK866 needed to arrest tumour growth, leading to persistent tumor regression 
in vivo (14).
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Intracellular NAMPT is ubiquitously present in human body, even if its expression varies according 
to tissues (46,49). Different experimental approaches have been exploited to define mitochondrial 
presence of NAMPT in different cell lines with controversial results (9,17,29,40,61). We found that 
also mitochondria are sensitive to NAMPT inhibition and that a small amount of NAMPT is present 
in these organelles. However, alternative explanations, such as cytosolic import of NAD+ cannot be 
excluded, as well as a cell type dependence of NAD+ biosynthetic pathways localization. At the 
concentrations used, NA raised NAD+ levels rescued FK866-dependent NAD+ depletion in all 
compartments, pointing to a very efficient NAPRT pathway. On the contrary, neither NR nor NAM 
raised NAD+ levels in mitochondria even though both NRK and NAMPT are present in the organelles. 
The finding that NMN induced a slight increase of mitochondrial NAD+ may reflect regulated 
transport of these metabolites. With the exception of QA, all tested NAD+ precursors, including 
NMN, are effective in boosting NAD+ levels in cytosol and nuclei. Among them, only NR is unable to 
rescue the FK866-induced NAD+ depletion in cytosol, in keeping with previous data that suggest that 
the NAM and NR pathways can both converge on NAMPT. According to these data, NR would be 
converted to NAM by a nucleoside phosphorylase prior to the NAMPT catalyzed reaction (5,36). This 
is in keeping with the very low levels of NR kinase in the cytosol, as demonstrated by western blot 
and confocal microscopy. 
Overall, our data provide a proof-of-principle of the validity of the use of organelle-specific 
biosensors to monitor NAD+ fluctuations that occur in physio-pathological conditions. They also 
reinforce the concept of compartmentalization of NAD+ biosynthesis, an essential aspect to 
understand how NAD+ metabolism impacts on cancer cell metabolic adaptation. By offering a more 
complete picture of NAD+ biosynthesis in MM, we aim to open the window of therapeutic strategies 
combining inhibitors of oncogenic signaling and of NAD+ biosynthesis.
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Innovation
In this study we used genetically encoded NAD+ biosensors to dynamically characterize subcellular 
NAD+ biosynthesis in intact BRAF-mutated metastatic melanoma (MM) cells. The choice of this 
model derives from our previous studies showing that melanoma transformation is accompanied 
by dysregulation of NAD+ biosynthesis, which may be therapeutically targeted. By using organelle 
specific biosensors, we monitored NAD+ fluctuations in response to biosynthetic precursors or 
inhibitors. Together with subcellular localization data, these results offer a complete picture of NAD+ 
biosynthesis in MM cells and open the way to the use of biosensors to understand the NADome 
architecture in physio-pathological conditions. 
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Material and Methods
CpVenus-based NAD+ sensor construct 
The NAD+ biosensor is a chimeric molecule, composed by a circularly permutated Venus (cpVenus) 
fluorescent protein linked to a bipartite NAD+-binding domain of a bacterial DNA ligase (LigA1b and 
LigA1a) (9,15,19). Cytosolic, nuclear and mitochondrial biosensor expression vectors were kindly 
provided by X.A. Cambronne (Department of Molecular Biosciences, University of Texas, Austin, 
USA). 
The incorporation of specific targeting sequences (CTGCAGAAAAAGCTGGAAGAGCTGGAACTGGAC 
for cytosol, ATGCTGGCCACCCGCGTGTTCAGCCTGGTGGGCAAGCGCGCCATCAGCACCAGCGTGTGCGT
GCGCGCCCAC for mitochondria, and CCAAAGAAGAAGCGTAAGGTA for nuclei), allows these 
biosensors to be expressed in an organelle-specific way. DNA was amplified, incorporated in 
lentiviral particles (see below) and used for stable cell transduction. The LigA-cpVENUS biosensor 
presents two excitation peaks, one at 488 nm that decreases according to NAD+ elevation and a 
second one at 405 nm that is unaffected by substrate variations, serving as internal control and 
system calibrator (9,15,19).
Generation of lentivirus
The vector plasmids (CMV-Sensor-IRES-puro-5 μg) together with third generation packaging 
plasmids (pMDL-2μg, pRSV-Rev-2μg, and the VSVG envelope encoding plasmid-1.2 μg, all from 
Addgene) were used for 293T cells transfection by using commercial Effectene transfection system 
(Quiagen, Milan, Italy, cod. 301425). After 48h, supernatants were collected, cells debris excluded 
(centrifugation at 600 x g for 5 minutes), and lentiviral particles concentrated (ultracentrifugation 
at 121,603 g for two hours) and used for cell transduction.
Generation of cell lines stably expressing biosensors
Page 23 of 56
Please destroy all records after use for peer review. Mary Ann Liebert Inc., 140 Huguenot Street, New Rochelle, NY 10801





























































CONFIDENTIAL. For Peer Review Only
Gaudino F., et al.
19
A375 BRAFV600E-mutated cell lines were from the American Type Culture Collection (ATCC). BRAFi-
resistant (BiR) variants were generated as described (2). Cells expressing cytosolic, nuclear or 
mitochondrial biosensors were obtained by transducing both A375/sensitive (S) and /BiR cells with 
a lentiviral vector carrying the specific organelle-targetable biosensor or with the organelle-
targetable cpVENUS alone, using polybrene (8ug/ml; Sigma, Milan, Italy, cod. H9268). cpVENUS 
positive cells were flow sorted (FACSAriaIII, BD Biosciences, Milan, Italy) and used as reported.
Cell treatments
A375/S and /BiR lines were cultured in RPMI-1640 (Sigma, cod. R6504) with 10% of fetal calf serum 
(FCS) (Sigma, cod. F7524) and 10 IU/ml of penicillin / streptomycin (Sigma, cod. P4333). Cells were 
exposed to the following treatments for 16 hours. For NAMPT inhibition, cells were treated with 25 
nM FK866 (Sigma, cod. F8557). Treatments with NAD+ precursors were with 500 μM NMN (cod. 
N3501), 6 μM NA (cod. N4126), 0.5 μM NAM (cod. N3376), 200 μM QA (cod. P63204 all from Sigma) 
and 100 μM NR (kind gift of ChromaDex, Irvine, CA).
Flow cytometry analysis
For flow cytometry analysis, cells were trypsinized (Sigma, cod. T4049) and collected in RPMI 10% 
FCS. Sensor/cpVenus FITC (excitation 488 nm, emission 530/30 nm) and BV510 (excitation 405 nm, 
emission 525/50 nm) were measured by flow cytometry (BD FACS Celesta) and data processed with 
DIVA version 8 (BD Biosciences) and FlowJo version 10.01 softwares (TreeStar, Ashland, OR). Cells 
were gated using forward scatter (FSC) and side scatter (SSC) for the live cells and then further gated 
on both SSC and FSC width to exclude doublets, analyzing at least 104 cells / sample. The analysis 
required a double ratio, expressed as a “ratio of ratios” (i.e. fold change). The first is the ratiometric 
488/405 measurement detected by the biosensor, the second one is obtained by the parallel 
analysis of 488 nm/405 nm fluorescence changes of cells expressing the cpVENUS-only control 
(9,15,19). The cpVENUS 488/405 nm fluorescence ratio is used to normalize for NAD+ changes 
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independent of the biosensor. F0 refers to the ratio of ratios obtained in untreated conditions 
(F0=1). NAD+ variations are finally expressed as the inverse relationship between the “ratio of ratios” 
changes and the cofactor concentrations. A “ratio of ratios” value >1 indicates decresed NAD+ 
concentrations, while values <1 indicate increased levels of NAD+.
Calibration curves 
Calibration curves of cytosolic and nuclear biosensors were generated as previously described (9). 
In details, cells expressing correspondent biosensors were permeabilized with saponin (0.005%), in 
the presence of propidium iodide (PI)(Sigma cod.P4170). Permeabilization status was monitored by 
looking at the percentage of PI positive cells. For mitochondrial biosensor-expressing cells, cells 
were first permeabilized for 10 minutes with saponin 0.005% and then treated with alamethicin 
(Sigma, cod. A4665) 30ug/ml in order to obtain mitochondria permeabilization and NAD+ exchange 
trough the organelle. Permeabilized cells were exposed to increasing concentrations (from 0 to 4 
mM for cytosol and nuclei and from 0 to 10 mM for mitochondria) of exogenous NAD+ (Sigma, cod. 
N-1511-1G). The NAD+-dependent fluorescence changes were monitored by flow cytometry. Each 
point composing the curve is the result of the ratio between 488nm and 405nm values of the 
biosensor normalized to the relative cpVENUS and lastly normalized on F0 (0 μM of NAD+).
Mitochondria purification
Mitochondria isolation was performed as previously described (21,32,63). Briefly, A375 cells 
(15x107) cells were resuspended in IBC buffer (200mM sucrose, 1mM Tris-HCL, 1 mM EGTA, pH 7.4). 
Cells were mechanically disrupted by using an Elvehjem potter (Sigma, cod. P7734), and suspension 
was centrifuged (600 x g, 10 min, 4°C). This step was repeated twice to increase purification 
efficiency. Pellet was discarded and mitochondria-containing supernatant was centrifuged (8,000 x 
g, 10 min, 4°C). A centrifugation (8,500 x g, 10min, 4°C) on a discontinuous Percoll gradient (60, 30 
and 18% Percoll, GE Healthcare, Milan, Italy, cod. GE17-0891-01), in IBc buffer, was used as last step 
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of purification. The fraction between the 30% and 18% gradients was collected and washed three 
times by centrifugation at 19,000 x g for 10 min. Purified mitochondria were then lysed in a 1% NP-
40 based buffer, subjected to Bradford quantification and prepared for western blot analysis with 
the same technical approach used for whole cell lysates (see below). 
Nuclei purification 
Nuclei were isolated through a salt-based protocol and differential centrifugation steps. Cells 
(8x106) were collected from culture and resuspended in Buffer A (300 mM Sucrose, 10 mM Hepes, 
10 mM KCl, 2 mM MgCl2, 1 mM EGTA, KOH pH 7.9, complete of phosphatase and protease 
inhibitors). To lyse cells, NP-40 (0,15%) was added to the suspension, before centrifuging (1300 x g, 
5 min) and the supernatant was centrifuged (16000 g, 15 min, 4C°) to eliminate membrane residues 
and used as cytosolic portion of the fractionating protocol. The pellet was then washed 5x in Buffer 
B (50 mM Hepes, 400 mM NaCl, 1 mM EDTA, pH 7.5 NAOH) (1300 g, 5 min) and subjected to 5 
sonication steps. Finally, the suspension was centrifuged (130000 g for 15 min) and the obtained 
supernatant used as pure nuclear protein fraction.
Western blot analysis 
Whole cells or subcellular fractions obtained as described above, were resolved by SDS-PAGE, and 
transferred to nitrocellulose filter membranes (Biorad, Milan, cod. 1704158) (2). After blocking (5% 
Not-fat dry milk, Santa Cruz Biotechnology, Heidelberg, Germany, cod. sc2325), membranes were 
incubated with: anti-GFP (Cell Signaling Technologies, Danvers, MA, cod 2555S), anti-vinculin 
(Abcam, Cambridge, UK, cod. 130007), -tubulin (Cell Signaling Technologies, cod.2114), -actin (Santa 
Cruz Biotechnology, cod. sc-47778), -Hadha (Abcam, cod. 203114), -cytochrome C (BD Bioscience, 
cod. 556433), -H2A (Abcam, cod. ab18255), anti-NAMPT (Bethyl Laboratories, Montgomery, TX 
A300-779A), anti-NAPRT1 (Novus Biologicals, Cambridge, UK, cod. NBP1-87243), anti-C9orf95 
(NRK1, ab169548) and anti-QPRT (ab57125 both from Abcam). After incubation with horseradish 
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peroxidase-conjugated secondary antibody (PerkinElmer, Milan, Italy, cod. NEF822001EA), reaction 
was visualized with ECL (Biorad, cod. 1705061) using ImageQuant LAS4000 (GE Healthcare, Milan, 
Italy). 
Confocal microscopy 
Cells expressing organelle-specific biosensors were cultured on glass cover slips in 24-well plates, 
rinsed once with PBS, fixed (4% PFA, 10 minutes, room temperature), permeabilized (0.1% saponin 
in PBS, 20 minutes, room temperature) and saturated with pre-immune goat serum (1:100, 1 hour, 
4 °C). For NBEs localization studies, after saturation cells were incubated with primary antibodies: 
anti-NAMPT, anti-NAPRT1, anti-C9orf95 and anti-QPRT, anti-TOM20 (cod. SC-11415 from Santa Cruz 
Biotechnology). MitoTracker Deep Red (ThermoFischer, cod. M22426). was used for mitochondria 
staining. TCS SP5 laser scanning confocal microscope equipped with an oil immersion 63X objective, 
was used for fluorescence acquisition. Images were acquired with LAS AF software (Leica 
Microsystem), files were processed with Photoshop (Adobe Systems, San Jose, CA) and pixel 
intensity was calculated using the ImageJ software (http://rsbweb.nih.gov/ij/).
Time lapse analysis
For time lapse imaging, A375 (12X105) were cultured into a μ-Slide 4 well Ibidi Chambered coverslips 
(Ibidi, Giemme Snc, Milan, Italy, cod. 80426), in RPMI-1640 with 10% of FCS. TCS SP5 was also 
equipped for maintaining cells under physiological conditions (5% CO2 and 37°C). for the duration 
of the experiments. At time 0 (t=0) cells were treated with FK866 25 nM, for a period of 6 hours. 
Time lapse series were acquired with 10 minutes intervals for mitochondrial and nuclear biosensor, 
for 5 minutes for cytosolic biosensor, between successive frames. To obtain the full cell thickness, 
for each acquisition field, different z-stacks were acquired and the sum of z stacks obtained with 
ImageJ software analysis was used for video generation. Finally, the ImageJ plugin ‘’image 
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calculator’’ was used to obtain the values of fluorescence ratio between 488nm and 405nm 
channels.
Statistical analysis 
Statistical analyses were performed with GraphPad version 6.0 (GraphPad Software Inc., La Jolla, 
CA). Data were analyzed by two-sided paired Student’s t test. Results are reported as box plots, 
where the top and bottom margins of the box define the 25th and 75th percentiles, the line in the 
box defines the median, and the error bars define the minimum and maximum of all data. P 
value<.05 was considered to be statistically significant. 
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Abbreviations Used
A375/S = A375 sensitive to BRAF inhibitors
A375/BiR = A375 resistant to BRAF inhibitors
AlaM = alamethicin
ARTs = adenosine diphosphate (ADP)-ribose transferases
BRAFi = BRAF inhibitor
cpVENUS = circularly permutated Venus protein
ETC = electron transport chain
GDP6 = glucose-6-phosphate dehydrogenase
GR = glutathione reductase
GSH = glutathione
GSSG = oxidized glutathione
HPLC = high performance liquid chromatography 
MM = metastatic melanoma
NA = nicotinic acid
NAD+ =nicotinamide adenine dinucleotide 
NADH = reduced nicotinamide adenine dinucleotide
NADP = nicotinamide adenine dinucleotide phosphate
NADPH = reduced nicotinamide adenine dinucleotide phosphate
NAM = nicotinamide 
NaMN = nicotinic acid mononucleotide
NAMPT = nicotinamide phosphoribosyltransferase 
NAMPTis = nicotinamide phosphoribosyltransferase inhibitors
NAPRT = nicotinate phosphoribosyltransferase
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NBEs = NAD+ biosynthetic enzymes
Ndt1p = mitochondrial NAD+ carrier protein
NMN = nicotinamide mononucleotide
NMNAT = nicotinamide mononucleotide adenylyltransferase 
NR = nicotinamide riboside
NRK = nicotinamide riboside kinase
PARPs = poly (ADP-ribose) polymerases
PRPP = phosphoribosylpyrophosphate
QA = quinolinic acid
QPRT = quinolinate phosphoribosyltransferase
SIRTs = sirtuins
TCA = tricarboxylic acid cycle
TR = thioredoxin reductase
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Figures Legends 
Figure 1. Generation of A375 cells stably expressing organelle-specific NAD+ biosensors 
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(A,B,C) Confocal microscopy : cells were cultured on glass cover slips in 24-well plates, fixed (4% 
PFA), permeabilized (0.1% saponin) and saturated with pre-immune goat serum. Cells were 
counterstained with phalloidin (red), TOM20 (magenta) and DAPI (blue) to highlight cytosol, 
mitochondria and nuclei, respectively. Fluorescence was acquired by confocal microscopy, using an 
oil immersion 63x objective. Slides were analyzed using a TCS SP5 laser scanning confocal 
microscope; images were acquired with LAS AF software Scale bar= 25μm for cytosolic A375 S/BiR, 
nuclear A375 S/BiR and mitochondrial A375/BiR; Scale bar= 10μm for mitochondrial A375/S. 
Diagrams on the top of each panel show the structure of the different constructs. A375/S : A375 
sensitive to BRAF inhibitors; A375/BiR : A375 resistant to BRAF inhibitors.
Figure 2. Effects of the NAMPT inhibitor FK866 
(A) Upper: quantification of time lapse imaging of A375 cells expressing the cytosolic, mitochondrial 
and nuclear biosensor, in response to FK866 (25nM, 4h period). Cells were cultured on Ibidi 
chambered coverslips and kept at 5% CO2 and 37°C during the experiment. Curves show the 
fluorescence ratio between 488 nm and 405 nm of th  biosensor reported as a function of time. 488 
nm and 405 nm fluorescence were separately recorded and the ratio was obtained by image 
calculator plugin of ImageJ software analysis. Curves are the results of 4 independent 
measurements. Lower: representative frames of A375 expressing relative biosensors at time (t) =0 
and t=4. Fluorescence was acquired by confocal microscopy, using an oil immersion 63x objective, 
in the figure A cropped images from zoomed acquisition fields are shown. NAD+ depletion can be 
followed by observing the increase of fluorescence intensity (movies 1-2-3). (B) NAD+ variations 
measured in A375 cytosol (C), mitochondria (M) and nuclei (N) after treatment with FK866 (25 nM, 
16 hours). Box plots are the results of 9 different experiments. Results are expressed as a “Ratio of 
Ratio” [F488/405(S/cpV)/F0]. Sensor/cpVenus (488 nm/405 nm) fluorescence ratios were measured 
by flow cytometry and the fold change compared with untreated controls (F0). (C) Representative 
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example of fluorescence variation of the cytosolic biosensor upon FK866 treatment in A375. Dot 
plot (on the left) and histogram (on the right) show the specificity of the NAMPT inhibitor -induced 
NAD+ depletion in increasing biosensor 488 nm fluorescence. UN: untreated.
Figure 3. Subcellular NAD+ concentrations and effects of NMN on subcellular NAD+ levels 
(A) Calibration curve of cytosolic, mitochondrial and nuclear biosensors obtained in A375. Cells were 
permeabilized with 0,005% saponin (cytosolic and nuclear biosensors) or with saponin and 
Alamethicin (mitochondrial biosensor expressing A375) and exposed to increased exogenous 
concentrations of NAD+. The fluorescence ratios (488 nm/405 nm) of the biosensor were normalized 
to cpVENUS. Diagrams show normalized fluorescence ratios (ƴ-axis) reported as a function of 
logarithmic NAD+ concentrations (x-axis) and fit with a variable slope model. Curves are the results 
of 4 independent experiments.(B) Intracellular NAD+ variations in A375 after treatment with NMN 
(0.5 mM, 16 hours), in presence or absence of FK866 25 nM (n=5). Results are expressed as a “Ratio 
of Ratio” [F488/405(S/coV)/F0]. Sensor/cpVenus (488 nm/405 nm) fluorescence ratios were 
measured by flow cytometry and the fold change was compared to untreated controls (F0). Two-
sided paired Student’s t test was used to determine statistical significance. Star marks refer to the 
significance of the relative change of each treatments condition compared to the untreated 
(untreated=1), while the p value refers to the rescue of supplementations from the FK866-treated 
condition. Boxes represent interquartile range, and the horizontal line across each box indicates the 
median. ns= not statistically significant.
Figure 4. Topography of NAD+ Biosynthesis: NAM and NA primarily affect cytosolic NAD+ levels
Cells were treated as follows: (A) 500 μM NAM ± 25 nM FK866; (B) 6 μM NA ± 25 nM FK866. Results 
are expressed as a “Ratio of Ratio” [F488/405(S/coV)/F0]. Sensor/cpVenus (488 nm/405 nm) 
fluorescence ratios were measured by flow cytometry and the fold change was compared to 
untreated controls (F0) (n=5). Star marks refer to the significance of the relative change of each 
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treatments condition compared to the untreated (untreated=1), while the p value refers to the 
rescue of supplementations from the FK866-treated condition.
Figure 5. Topography of NAD+ Biosynthesis: NR and QA showed an organelle-specific impact on 
NAD+ levels
Cells were treated with (C) 100 μM NR ± 25 nM FK866; (D) 200 μM QA ± 25 nM FK866. A375 cells 
were exposed to the treatments for 16 hours. Results are expressed as a “Ratio of Ratio” 
[F488/405(S/coV)/F0]. Sensor/cpVenus (488 nm/405 nm) fluorescence ratios were measured by 
flow cytometry and the fold change was compared to untreated controls (F0) (n=5). Star marks refer 
to the significance of the relative change of each treatments condition compared to the untreated 
(untreated=1), while the p value refers to the rescue of supplementations from the FK866-treated 
condition.
Figure 6. Subcellular localization of NAD+ biosynthetic enzymes
(A) Mitochondria and nuclei were isolated as described in material and methods. 10μg of each lysate 
were loaded in the following order: whole cell lysat  (WCL), cytosolic fraction (C), mitochondrial 
fraction (M) and nuclear fraction (N). Anti-Vinculin, anti-tubulin, anti-actin, anti-Hadha, anti-
cytochrome c and anti-H2A were used to determine the purity of cytosolic, mitochondrial and 
nuclear fractions, respectively. (B) Graph represents the percentage of NBEs expression in each 
fraction. Band quantification was performed using ImageQuant software. Values are referred to the 
mean of 6 independent experiments. % was calculated as: % of pixel intensity of district specific 
band/sum of all districts pixel intensities. (C) On the left confocal microscopy showing NAMPT, 
NAPRT, NRK, QPRT total expression (green fluorescence) in whole cells (merge). Cytosol, 
mitochondria and nuclei were counterstained with phalloidin (red), MitoTracker (magenta) and 
DAPI (blue) respectively (zoomed image of 63X magnification, scale bar= 10μm). On the right NBEs-
cytosol/mitochondria/nuclei sub-localization. In detail, NAMPT, NAPRT, NRK and QPRT (green 
Page 42 of 56
Please destroy all records after use for peer review. Mary Ann Liebert Inc., 140 Huguenot Street, New Rochelle, NY 10801





























































CONFIDENTIAL. For Peer Review Only
Gaudino F., et al.
38
fluorescence) were localized by delimiting fractions (red fluorescence) separately by using the co-
localization tool of LAS AF Version Lite 2.4 software. Representative images show single NBE and 
single compartment overlapping (image of 63X magnification, scale bar= 25μm).
Figure 7. A375/S and /BiR responses to the NAMPT inhibition 
Cytosolic, mitochondrial and nuclear NAD+ variations were measured in BRAFi-sensitive (S) or 
resistant (BiR) cells after treatment with FK866 (25 nM, 16 hours). Results are expressed as relative 
fold change [F488/405(S/coV)/F0]. Sensor/cpVenus (488 nm/405 nm) fluorescence ratios were 
measured by flow cytometry and the fold change was compared to untreated (F0). Box plot 
representing 9 independent experiments. Star marks refers to the relative change of FK866 
treatment compared to 1 (untreated), while p value indicates significance of the FK866 differential 
response of A375/BiR compared to A375/S. 
Figure 8. Compartmentalization of NAD+ biosynthesis in A375 MM
On the top schematic representation of biochemical reactions involved in NAD+ production. NAD+ 
precursors present in the extracellular space can enter the cell becoming substrates of the NBEs. QA 
enters in the de novo biosynthetic pathway, while NA, NR and NAM are substrates of the parallel 
three salvage pathways. Among the NAD+ precursors NAM is also the by-product of NAD+ consuming 
enzymes such as sirtuins and PARPs. NAM and NR can be used to produce NMN by NAMPT and 
NRKs, respectively. NMN and NaMN (produced by NAPRT-mediated Na conversion) are finally used 
by compartmentalized NMNATs to generate NAD+. In the center, an A375 melanoma cell acquired 
by using confocal microscope. Cytosol, mitochondria and nuclei were counterstained with phalloidin 
(red), MitoTracker (magenta) and DAPI (blue) respectively (zoomed image of 63X magnification 
acquired by confocal microscopy , a cropped image is shown). Insets of A375 cytosol, nucleus and 
mitochondria resume the most relevant NBEs found in each A375 subcellular districts. Enzymes 
written in bold are the most expressed NBEs in the highlighted cell districts, while percentage refers 
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to the expression level of each enzymes in each compartment. The cytosolic picture of A375 NAD+ 
biosynthesis is composed by a dominant cytosolic NAMPT pathway converting NAM into NMN. 
NAPRT can be considered a second, but highly active, enzyme which mediates the cytosolic NA 
conversion to NaMN, indeed its localization was found to be more than 92% cytosolic. These 
pathways contribute to the generation of an NAD+ pool calculated to be around 261 μM. In the 
nucleus, the NAD+ pool is approximately 258 μM and the primary expressed NBEs is NRK. In this 
compartment, we were also able to detect low levels of NAMPT and NAPRT (5.1% and 2% of their 
total expression, respectively). NRK expression is also prevalent in mitochondria (67.2 % of its total 
biochemical detection), where the calculated NAD+ concentration is 499 μM. In this organelle, low 
expression of NAMPT (10.74%) and NAPRT (5.7%) could contribute to the maintenance of 
mitochondrial NAD+ pool. 
Table 1. Fluorescence variations of each biosensors in the presence of NAD+
Table showing cpVENUS normalized fluorescence variations of each biosensors when exposed to 
increasing concentrations of exogenous NAD+ in a condition of saponin or saponin/alamethicin-
mediated permeabilization. Reported numbers are the mean of four independent experiments for 
cytosolic and nuclear biosensor, of three independent experiments for mitochondrial biosensor.
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Figure 1. Generation of A375 cells stably expressing organelle-specific NAD+ biosensors 
(A,B,C) Confocal microscopy : cells were cultured on glass cover slips in 24-well plates, fixed (4% PFA), 
permeabilized (0.1% saponin) and saturated with pre-immune goat serum. Cells were counterstained with 
phalloidin (red), TOM20 (magenta) and DAPI (blue) to highlight cytosol, mitochondria and nuclei, 
respectively. Fluorescence was acquired by confocal microscopy, using an oil immersion 63x objective. 
Slides were analyzed using a TCS SP5 laser scanning confocal microscope; images were acquired with LAS 
AF software Scale bar= 25μm for cytosolic A375 S/BiR, nuclear A375 S/BiR and mitochondrial A375/BiR; 
Scale bar= 10μm for mitochondrial A375/S. Diagrams on the top of each panel show the structure of the 
different constructs. A375/S : A375 sensitive to BRAF inhibitors; A375/BiR : A375 resistant to BRAF 
inhibitors.
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Figure 2. Effects of the NAMPT inhibitor FK866 
(A) Upper: quantification of time lapse imaging of A375 cells expressing the cytosolic, mitochondrial and 
nuclear biosensor, in response to FK866 (25nM, 4h period). Cells were cultured on Ibidi chambered 
coverslips and kept at 5% CO2 and 37°C during the experiment. Curves show the fluorescence ratio 
between 488 nm and 405 nm of the biosensor reported as a function of time. 488 nm and 405 nm 
fluorescence were separately recorded and the ratio was obtained by image calculator plugin of ImageJ 
software analysis. Curves are the results of 4 independent measurements. Lower: representative frames of 
A375 expressing relative biosensors at time (t) =0 and t=4. Fluorescence was acquired by confocal 
microscopy, using an oil immersion 63x objective, in the figure A cropped images from zoomed acquisition 
fields are shown. NAD+ depletion can be followed by observing the increase of fluorescence intensity 
(movies 1-2-3). (B) NAD+ variations measured in A375 cytosol (C), mitochondria (M) and nuclei (N) after 
treatment with FK866 (25 nM, 16 hours). Box plots are the results of 9 different experiments. Results are 
expressed as a “Ratio of Ratio” [F488/405(S/cpV)/F0]. Sensor/cpVenus (488 nm/405 nm) fluorescence 
ratios were measured by flow cytometry and the fold change compared with untreated controls (F0). (C) 
Representative example of fluorescence variation of the cytosolic biosensor upon FK866 treatment in A375. 
Dot plot (on the left) and histogram (on the right) show the specificity of the NAMPT inhibitor -induced 
NAD+ depletion in increasing biosensor 488 nm fluorescence. UN: untreated.
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Figure 3. Subcellular NAD+ concentrations and effects of NMN on subcellular NAD+ levels 
(A) Calibration curve of cytosolic, mitochondrial and nuclear biosensors obtained in A375. Cells were 
permeabilized with 0,005% saponin (cytosolic and nuclear biosensors) or with saponin and Alamethicin 
(mitochondrial biosensor expressing A375) and exposed to increased exogenous concentrations of NAD+. 
The fluorescence ratios (488 nm/405 nm) of the biosensor were normalized to cpVENUS. Diagrams show 
normalized fluorescence ratios (ƴ-axis) reported as a function of logarithmic NAD+ concentrations (x-axis) 
and fit with a variable slope model. Curves are the results of 4 independent experiments.(B) Intracellular 
NAD+ variations in A375 after treatment with NMN (0.5 mM, 16 hours), in presence or absence of FK866 25 
nM (n=5). Results are expressed as a “Ratio of Ratio” [F488/405(S/coV)/F0]. Sensor/cpVenus (488 nm/405 
nm) fluorescence ratios were measured by flow cytometry and the fold change was compared to untreated 
controls (F0). Two-sided paired Student’s t test was used to determine statistical significance. Star marks 
refer to the significance of the relative change of each treatments condition compared to the untreated 
(untreated=1), while the p value refers to the rescue of supplementations from the FK866-treated condition. 
Boxes represent interquartile range, and the horizontal line across each box indicates the median. ns= not 
statistically significant.
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Figure 4. Topography of NAD+ Biosynthesis: NAM and NA primarily affect cytosolic NAD+ levels
Cells were treated as follows: (A) 500 μM NAM ± 25 nM FK866; (B) 6 μM NA ± 25 nM FK866. Results are 
expressed as a “Ratio of Ratio” [F488/405(S/coV)/F0]. Sensor/cpVenus (488 nm/405 nm) fluorescence 
ratios were measured by flow cytometry and the fold change was compared to untreated controls (F0) 
(n=5). Star marks refer to the significance of the relative change of each treatments condition compared to 
the untreated (untreated=1), while the p value refers to the rescue of supplementations from the FK866-
treated condition.
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Figure 5. Topography of NAD+ Biosynthesis: NR and QA showed an organelle-specific impact on NAD+ 
levels
Cells were treated with (C) 100 μM NR ± 25 nM FK866; (D) 200 μM QA ± 25 nM FK866. A375 cells were 
exposed to the treatments for 16 hours. Results are expressed as a “Ratio of Ratio” [F488/405(S/coV)/F0]. 
Sensor/cpVenus (488 nm/405 nm) fluorescence ratios were measured by flow cytometry and the fold 
change was compared to untreated controls (F0) (n=5). Star marks refer to the significance of the relative 
change of each treatments condition compared to the untreated (untreated=1), while the p value refers to 
the rescue of supplementations from the FK866-treated condition.
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Figure 6. Subcellular localization of NAD+ biosynthetic enzymes
(A) Mitochondria and nuclei were isolated as described in material and methods. 10μg of each lysate were 
loaded in the following order: whole cell lysate (WCL), cytosolic fraction (C), mitochondrial fraction (M) and 
nuclear fraction (N). Anti-Vinculin, anti-tubulin, anti-actin, anti-Hadha, anti-cytochrome c and anti-H2A were 
used to determine the purity of cytosolic, mitochondrial and nuclear fractions, respectively. (B) Graph 
represents the percentage of NBEs expression in each fraction. Band quantification was performed using 
ImageQuant software. Values are referred to the mean of 6 independent experiments. % was calculated as: 
% of pixel intensity of district specific band/sum of all districts pixel intensities. (C) On the left confocal 
microscopy showing NAMPT, NAPRT, NRK, QPRT total expression (green fluorescence) in whole cells 
(merge). Cytosol, mitochondria and nuclei were counterstained with phalloidin (red), MitoTracker (magenta) 
and DAPI (blue) respectively (zoomed image of 63X magnification, scale bar= 10μm). On the right NBEs-
cytosol/mitochondria/nuclei sub-localization. In detail, NAMPT, NAPRT, NRK and QPRT (green fluorescence) 
were localized by delimiting fractions (red fluorescence) separately by using the co-localization tool of LAS 
AF Version Lite 2.4 software. Representative images show single NBE and single compartment overlapping 
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(image of 63X magnification, scale bar= 25μm).
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Figure 7. A375/S and /BiR responses to the NAMPT inhibition 
Cytosolic, mitochondrial and nuclear NAD+ variations were measured in BRAFi-sensitive (S) or resistant 
(BiR) cells after treatment with FK866 (25 nM, 16 hours). Results are expressed as relative fold change 
[F488/405(S/coV)/F0]. Sensor/cpVenus (488 nm/405 nm) fluorescence ratios were measured by flow 
cytometry and the fold change was compared to untreated (F0). Box plot representing 9 independent 
experiments. Star marks refers to the relative change of FK866 treatment compared to 1 (untreated), while 
p value indicates significance of the FK866 differential response of A375/BiR compared to A375/S. 
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Figure 8. Compartmentalization of NAD+ biosynthesis in A375 MM
On the top schematic representation of biochemical reactions involved in NAD+ production. NAD+ 
precursors present in the extracellular space can enter the cell becoming substrates of the NBEs. QA enters 
in the de novo biosynthetic pathway, while NA, NR and NAM are substrates of the parallel three salvage 
pathways. Among the NAD+ precursors NAM is also the by-product of NAD+ consuming enzymes such as 
sirtuins and PARPs. NAM and NR can be used to produce NMN by NAMPT and NRKs, respectively. NMN and 
NaMN (produced by NAPRT-mediated Na conversion) are finally used by compartmentalized NMNATs to 
generate NAD+. In the center, an A375 melanoma cell acquired by using confocal microscope. Cytosol, 
mitochondria and nuclei were counterstained with phalloidin (red), MitoTracker (magenta) and DAPI (blue) 
respectively (zoomed image of 63X magnification acquired by confocal microscopy , a cropped image is 
shown). Insets of A375 cytosol, nucleus and mitochondria resume the most relevant NBEs found in each 
A375 subcellular districts. Enzymes written in bold are the most expressed NBEs in the highlighted cell 
districts, while percentage refers to the expression level of each enzymes in each compartment. The 
cytosolic picture of A375 NAD+ biosynthesis is composed by a dominant cytosolic NAMPT pathway 
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converting NAM into NMN. NAPRT can be considered a second, but highly active, enzyme which mediates the 
cytosolic NA conversion to NaMN, indeed its localization was found to be more than 92% cytosolic. These 
pathways contribute to the generation of an NAD+ pool calculated to be around 261 μM. In the nucleus, the 
NAD+ pool is approximately 258 μM and the primary expressed NBEs is NRK. In this compartment, we were 
also able to detect low levels of NAMPT and NAPRT (5.1% and 2% of their total expression, respectively). 
NRK expression is also prevalent in mitochondria (67.2 % of its total biochemical detection), where the 
calculated NAD+ concentration is 499 μM. In this organelle, low expression of NAMPT (10.74%) and NAPRT 
(5.7%) could contribute to the maintenance of mitochondrial NAD+ pool. 
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Table 1. Fluorescence variations of each biosensors in the presence of NAD+ 
Table showing cpVENUS normalized fluorescence variations of each biosensors when exposed to increasing 
concentrations of exogenous NAD+ in a condition of saponin or saponin/alamethicin-mediated 
permeabilization. Reported numbers are the mean of four independent experiments for cytosolic and nuclear 
biosensor, of three independent experiments for mitochondrial biosensor. 
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